Compound profile
Cerebrolysin
Limited human dataAlso known as: FPF 1070 · porcine-brain-derived peptide preparation
A mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain proteins, approved in several countries for stroke and traumatic brain injury recovery. Distinct from single-sequence research peptides: it's a multi-component biological preparation.
Overview
Cerebrolysin is not a single peptide but a standardized mixture of low molecular weight peptides and free amino acids derived from purified porcine brain tissue through a controlled enzymatic hydrolysis process. Roughly three quarters of the preparation by weight is free amino acids, around 17 different ones, and the remaining quarter is made up of small peptide fragments under 10,000 daltons, some of which researchers have identified as resembling fragments of natural neurotrophic factors, including brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, nerve growth factor, ciliary neurotrophic factor, and insulin-like growth factors 1 and 2.
Its origins go back to 1949 in Vienna, where it began as an experimental treatment explored for soldiers with traumatic brain injuries. The modern, standardized version of the product was developed starting in the 1970s by the Austrian company then known as EBEWE, now EVER Neuro Pharma, which industrialized the manufacturing process into the consistent, quality-controlled preparation studied in later clinical trials.
Cerebrolysin is approved for clinical use in more than 50 countries, including Austria, Germany, Russia, China, and South Korea, primarily for stroke recovery and cognitive impairment following traumatic brain injury, with decades of clinical use across those regions. It has never been approved by the FDA in the United States, where it is available only as a research-use compound, and this multi-component, non-single-molecule identity sets it apart from every other peptide discussed on this site, since it cannot be described by a single amino acid sequence and its exact active ingredient or ingredients have not been isolated to the degree a single synthetic peptide can be.
Mechanism (plain language)
Proposed to act through multiple neurotrophic and neuroprotective pathways simultaneously (rather than one receptor), since it contains a mixture of naturally occurring peptide fragments rather than a single defined active compound.
How it works
Because Cerebrolysin is a mixture rather than a single defined compound, its proposed mechanism is described as acting through multiple neurotrophic and neuroprotective pathways at the same time rather than through one specific receptor, which is a meaningfully different pharmacological model than the single-target peptides most commonly discussed in research communities. Its peptide fraction contains fragments that researchers describe as similar to naturally occurring growth factors involved in neuron survival, the formation of new synapses, and the growth of new blood vessels in brain tissue, and it is proposed to support these repair processes broadly during recovery from brain injury.
This multi-target, mixture-based mechanism is central to both the interest in Cerebrolysin and the difficulty in studying it rigorously. A single peptide's mechanism can be tested by blocking or mimicking one specific receptor interaction, but a complex mixture like Cerebrolysin resists that kind of precise mechanistic isolation, since any observed effect could plausibly come from many different components acting together rather than from one attributable active ingredient, which is a genuinely different scientific situation from validating a single synthetic peptide's mechanism of action.
What research suggests
Multiple randomized, placebo-controlled multicenter trials (including the CARS trial in stroke) report improved motor and global-outcome scores versus placebo, and meta-analyses in traumatic brain injury report favorable effects on functional outcome scales.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Motor function recovery after stroke
The CARS trial, a randomized, placebo-controlled, double-blind multicenter study, reported improved upper-extremity motor function and global outcome scores at day 90 with Cerebrolysin added to early post-stroke rehabilitation.
Neurological outcome scores after acute ischemic stroke
A separate randomized multicenter trial reported significantly better NIH Stroke Scale outcomes with Cerebrolysin versus placebo at day 30 in the early recovery period after stroke.
Functional outcomes in traumatic brain injury
Meta-analyses pooling multiple trials in traumatic brain injury report favorable effects on functional outcome scales, supporting its approved use for this indication in a number of countries.
Decades of international clinical use
Beyond individual trials, Cerebrolysin has an extended track record of approved clinical use across more than 50 countries for stroke and brain injury recovery, giving it more real-world use history than most peptides in this category.
Uncertainties & risks
Trial quality and effect sizes are heterogeneous across studies, with some meta-analyses flagging high statistical heterogeneity and calling for larger confirmatory trials. As a mixture rather than a single peptide, exact active-component attribution is unresolved. Not approved by the FDA for use in the United States.
Cerebrolysin's trial base is larger than most peptides discussed here, including multiple randomized, placebo-controlled, multicenter studies, but the quality and consistency of that evidence varies. Some meta-analyses in both stroke and traumatic brain injury note substantial statistical heterogeneity across trials, meaning individual studies do not always agree closely on effect size, and reviewers have called for larger, more consistently designed confirmatory trials before treating the effect as fully settled. Because it is a mixture rather than a single defined peptide, exactly which components drive whatever benefit is observed remains unresolved, an inherent limitation of studying a complex biological preparation rather than a pure synthetic compound with a known structure. It is not FDA approved in the United States, where it is available only for research use rather than as a prescribed treatment, even though it carries genuine drug approval and clinical use history in dozens of other countries. As a porcine tissue-derived biological product, questions specific to that origin, including batch-to-batch consistency and any theoretical risk associated with animal tissue-derived preparations, are also part of its overall risk profile in a way that does not apply to fully synthetic peptides.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.